Michael Makris/LinkedIn
Oct 30, 2025, 03:53
Michael Makris on Biomarin’s Decision to Divest Roctavian
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”Important.
Biomarin, the only manufacturer of an approved hemophilia A gene therapy has decided to divest Roctavian and remove it from their portfolio.
They plan to sell it on to a more established hemophilia company, if they can find a buyer.
The problems have been the high cost and limited durability.
This is a sad turn of events but not surprising to anybody who follows the field.
We suspected that sales were poor, but not this poor, as indicated in their press release.
This is their press release.”
Stay updated with Hemostasis Today.
-
Sep 22, 2026, 07:59Cesar de Almeida Neto: Jehovah’s Witnesses Update Their Position on Blood Components
-
Sep 22, 2026, 07:39Better Trials and Better Treatments Through Greater Inclusion – American Society of Hematology
-
Sep 22, 2026, 07:18X. Long Zheng: From ADAMTS13 to New TTP Treatment
-
Sep 22, 2026, 07:11Platelet Dependent Protection Against Bacterial Pneumonia – JTH
-
Sep 22, 2026, 07:10Sumita Pandey: Apheresis Beyond Automation
-
Sep 22, 2026, 07:04Wafik El-Deiry: Type 1 interferon Alters Clonal Competition in Human Blood Development
-
Sep 22, 2026, 06:53Tania L.: Women in Hematology Take the Stage in Austin
-
Sep 22, 2026, 06:35Mahmoud Hanafy: Hayat National Hospitals Achieves AABB Accreditation
-
Sep 22, 2026, 06:01Nikola Pantic: New ASH ITP Guidelines Transform First-Line Treatment